Nurtec Odt Tablet, Orally Disintegrating
Product Images NDC 85766-096

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Nurtec Odt (NDC 85766-096). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sportpharm Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

F0741274 9808 5644 E053 2995a90a021e

F0741274 9808 5644 E053 2995a90a021e
FDA Label Image

1 (Label)

1 (Label)
FDA Label Image

Image (Nurtec 01)

Image (Nurtec 01)
FDA Label Image

Chemical Structure (Nurtec 02)

Chemical Structure (Nurtec 02)
FDA Label Image

Figure 1 (Nurtec 03)

Figure 1 (Nurtec 03)
This data shows the percentage of participants achieving pain freedom over time after taking NURTEC ODT 75 mg compared to a placebo. The chart indicates that 100% of participants achieved pain freedom with NURTEC ODT, while the placebo had a lower percentage. Time increments from 0 hours to 24 hours are also displayed on the chart.*
FDA Label Image

Figure 2 (Nurtec 04)

Figure 2 (Nurtec 04)
This description provides a visualization of the percentage of individuals achieving relief with MBS Freedom at different time intervals after taking NURTEC ODT 75 mg compared to a placebo. The graph shows the increase in the percentage of individuals achieving relief over time, with a peak of 100% at 1.5 hours after the dose. This data suggests the effectiveness and rapid action of NURTEC ODT 75 mg in providing relief compared to a placebo.*
FDA Label Image

Figure 3 (Nurtec 05)

Figure 3 (Nurtec 05)
FDA Label Image

Figure 4 (Nurtec 06)

Figure 4 (Nurtec 06)
This text provides data on the percentage of patients experiencing a reduction in migraine days per month based on the treatment received (Placebo vs. Rimegepant 75 mg). The data is presented in a table format specifying the number of patients in each group and the percentage of patients falling into different categories of migraine days reduction. The text aims to compare the efficacy of the two treatments in reducing the frequency of migraine days per month.*
FDA Label Image

Image (Nurtec 07)

Image (Nurtec 07)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.